Xeris Biopharma: 1st patient dosed in study of XP-8121 to treat hypothyroidism

Xeris Biopharma Holdings announced that the first participant has been dosed in a multi-center, open label, Phase 2 study of XP-8121 for the treatment of adults with hypothyroidism. “Oral levothyroxine is one of the most prescribed medicines in the United States, generating more than 100 million prescriptions per year. However, many patients experience one or more challenges associated with the oral therapy. We believe that our novel SC formulation of levothyroxine has the potential to provide patients with a once-weekly dosing, thereby potentially improving treatment adherence, as well as bypass the gastrointestinal tract,” said Paul R. Edick, Xeris’ Chairman and CEO. “We are excited to have dosed the first participant in our Phase 2 dose-finding study of XP-8121 and are actively recruiting additional participants that meet the eligibility criteria. We anticipate a lengthy recruitment period as enrolling stably dosed patients with normal TSH on oral levothyroxine is challenging and speaks further to the need of developing a once-weekly SC injection,” said Kenneth E. Johnson, PharmD, Xeris’ Senior Vice President, Global Development and Medical Affairs. “Depending upon enrollment rates, we anticipate completing the study in the first half of 2024.”